Insulin glargine

Details

Files

Generic Name:

Insulin glargine

Project Status:

Complete

Therapeutic Area:

Diabetes mellitus, type 1; diabetes mellitus, type 2

Manufacturer:

Eli Lilly Canada Inc.

Call for patient/clinician input open:

September 4, 2015

Brand Name:

Basaglar

Project Line:

Reimbursement Review

Project Number:

SE0451-000

Call for patient/clinician input closed:

October 27, 2015

NOC Status at Filing:

Post NOC

Submission Type:

Initial

Indications:

Diabetes mellitus, Type 1 & 2

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

April 14, 2016

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Patient Group Input Submissions View PDF

Subsequent Entry Biologic Review Report View PDF

Last Updated : September 4, 2015